;PMID: 1807447
;source_file_1953.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)sentence:[e:48..122] = [t:48..122]
;2)section:[e:126..194] = [t:126..194]
;3)section:[e:198..301] = [t:198..301]
;4)sentence:[e:305..470] = [t:305..470]
;5)sentence:[e:471..564] = [t:471..564]
;6)sentence:[e:565..762] = [t:565..762]
;7)sentence:[e:763..938] = [t:763..938]
;8)sentence:[e:939..1284] = [t:939..1284]
;9)sentence:[e:1285..1376] = [t:1285..1376]
;10)sentence:[e:1377..1519] = [t:1377..1519]
;11)sentence:[e:1520..1630] = [t:1520..1630]
;12)sentence:[e:1631..1739] = [t:1631..1739]
;13)sentence:[e:1740..1940] = [t:1740..1940]
;14)section:[e:1944..1988] = [t:1944..1988]

;section 0 Span:0..42
;Chem Res Toxicol. 1991 Nov-Dec;4(6):642-7.
(SEC
  (FRAG (NNP:[0..4] Chem) (NNP:[5..8] Res) (NNP:[9..16] Toxicol) (.:[16..17] .)
        (CD:[18..22] 1991) (NNP:[23..27] Nov-) (CD:[27..33] Dec;4-LRB-)
        (CD:[33..35] 6-RRB-) (CD:[35..39] :642) (HYPH:[39..40] -)
        (CD:[40..42] 7.)))

;sentence 1 Span:48..122
;Inhibition of cytochrome P-450 2E1 by diallyl sulfide and its metabolites.
;[62..82]:cyp450:"cytochrome P-450 2E1"
;[86..101]:substance:"diallyl sulfide"
;[110..121]:substance:"metabolites"
(SENT
  (NP-HLN
    (NP (NN:[48..58] Inhibition))
    (PP (IN:[59..61] of)
      (NP
        (NML (NN:[62..72] cytochrome) (NN:[73..78] P-450))
        (NN:[79..82] 2E1)))
    (PP (IN:[83..85] by)
      (NP
        (NP (JJ:[86..93] diallyl) (NN:[94..101] sulfide))
        (CC:[102..105] and)
        (NP (PRP$:[106..109] its) (NNS:[110..121] metabolites))))
    (.:[121..122] .)))

;section 2 Span:126..194
;Brady JF, Ishizaki H, Fukuto JM, Lin MC, Fadel A, Gapac JM, Yang CS.
(SEC
  (FRAG (NNP:[126..131] Brady) (NNP:[132..134] JF) (,:[134..135] ,)
        (NNP:[136..144] Ishizaki) (NNP:[145..146] H) (,:[146..147] ,)
        (NNP:[148..154] Fukuto) (NNP:[155..157] JM) (,:[157..158] ,)
        (NNP:[159..162] Lin) (NNP:[163..165] MC) (,:[165..166] ,)
        (NNP:[167..172] Fadel) (NNP:[173..174] A) (,:[174..175] ,)
        (NNP:[176..181] Gapac) (NNP:[182..184] JM) (,:[184..185] ,)
        (NNP:[186..190] Yang) (NNP:[191..193] CS) (.:[193..194] .)))

;section 3 Span:198..301
;Laboratory for Cancer Research, College of Pharmacy, Rutgers University, 
;Piscataway, New Jersey 08855.
(SEC
  (FRAG (NN:[198..208] Laboratory) (IN:[209..212] for) (NNP:[213..219] Cancer)
        (NNP:[220..228] Research) (,:[228..229] ,) (NNP:[230..237] College)
        (IN:[238..240] of) (NNP:[241..249] Pharmacy) (,:[249..250] ,)
        (NNP:[251..258] Rutgers) (NNP:[259..269] University) (,:[269..270] ,)
        (NNP:[272..282] Piscataway) (,:[282..283] ,) (NNP:[284..287] New)
        (NNP:[288..294] Jersey) (CD:[295..300] 08855) (.:[300..301] .)))

;sentence 4 Span:305..470
;Diallyl sulfide, a major flavor ingredient from garlic, was previously shown
;to  inhibit chemically induced carcinogenesis and cytotoxicity in animal
;model  systems.
;[305..320]:substance:"Diallyl sulfide"
;[337..347]:substance:"ingredient"
;[353..359]:substance:"garlic"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[305..312] Diallyl) (NN:[313..320] sulfide))
      (,:[320..321] ,)
      (NP
        (NP (DT:[322..323] a) (JJ:[324..329] major) (NN:[330..336] flavor)
            (NN:[337..347] ingredient))
        (PP (IN:[348..352] from)
          (NP (NN:[353..359] garlic)))))
    (,:[359..360] ,)
    (VP (VBD:[361..364] was)
      (ADVP (RB:[365..375] previously))
      (VP (VBN:[376..381] shown)
        (S
          (NP-SBJ-1 (-NONE-:[381..381] *))
          (VP (TO:[382..384] to)
            (VP (VB:[386..393] inhibit)
              (NP
                (NP
                  (ADJP-2 (RB:[394..404] chemically) (VBN:[405..412] induced))
                  (NN:[413..427] carcinogenesis))
                (CC:[428..431] and)
                (NP
                  (ADJP-2 (-NONE-:[431..431] *P*))
                  (NN:[432..444] cytotoxicity)))
              (PP (IN:[445..447] in)
                (NP (NN:[448..454] animal) (NN:[455..460] model)
                    (NNS:[462..469] systems))))))))
    (.:[469..470] .)))

;sentence 5 Span:471..564
;It modulated cytochrome P-450 compositions by inactivating P-450 2E1  and
;inducing P-450 2B1.
;[484..500]:cyp450:"cytochrome P-450"
;[530..539]:cyp450:"P-450 2E1"
;[554..563]:cyp450:"P-450 2B1"
(SENT
  (S
    (NP-SBJ (PRP:[471..473] It))
    (VP (VBD:[474..483] modulated)
      (NP
        (NML (NN:[484..494] cytochrome) (NN:[495..500] P-450))
        (NNS:[501..513] compositions))
      (PP (IN:[514..516] by)
        (S-NOM
          (NP-SBJ (-NONE-:[516..516] *))
          (VP
            (VP (VBG:[517..529] inactivating)
              (NP (NN:[530..535] P-450) (NN:[536..539] 2E1)))
            (CC:[541..544] and)
            (VP (VBG:[545..553] inducing)
              (NP (NN:[554..559] P-450) (NN:[560..563] 2B1)))))))
    (.:[563..564] .)))

;sentence 6 Span:565..762
;The present studies examined the inhibition of P-450 2E1  mediated
;p-nitrophenol hydroxylase activity by diallyl sulfide and its putative 
;metabolites diallyl sulfoxide and diallyl sulfone (DASO2).
;[612..621]:cyp450:"P-450 2E1"
;[632..657]:cyp450:"p-nitrophenol hydroxylase"
;[670..685]:substance:"diallyl sulfide"
;[704..715]:substance:"metabolites"
;[716..733]:substance:"diallyl sulfoxide"
;[738..753]:substance:"diallyl sulfone"
;[755..760]:substance:"DASO2"
(SENT
  (S
    (NP-SBJ (DT:[565..568] The) (JJ:[569..576] present) (NNS:[577..584] studies))
    (VP (VBD:[585..593] examined)
      (NP
        (NP (DT:[594..597] the) (NN:[598..608] inhibition))
        (PP (IN:[609..611] of)
          (NP
            (ADJP
              (NML (NN:[612..617] P-450) (NN:[618..621] 2E1))
              (VBN:[623..631] mediated))
            (NML (NN:[632..645] p-nitrophenol) (NN:[646..657] hydroxylase))
            (NN:[658..666] activity)))
        (PP (IN:[667..669] by)
          (NP
            (NP (JJ:[670..677] diallyl) (NN:[678..685] sulfide))
            (CC:[686..689] and)
            (NP
              (NP (PRP$:[690..693] its) (JJ:[694..702] putative)
                  (NNS:[704..715] metabolites))
              (NP
                (NP (JJ:[716..723] diallyl) (NN:[724..733] sulfoxide))
                (CC:[734..737] and)
                (NP
                  (NP (JJ:[738..745] diallyl) (NN:[746..753] sulfone))
                  (NP (-LRB-:[754..755] -LRB-) (NN:[755..760] DASO2)
                      (-RRB-:[760..761] -RRB-)))))))))
    (.:[761..762] .)))

;sentence 7 Span:763..938
;Each compound  displayed competitive inhibition of p-nitrophenol hydroxylase
;activity in  incubations using liver microsomes from acetone-pretreated male
;Sprague-Dawley  rats.
;[768..776]:substance:"compound"
;[814..839]:cyp450:"p-nitrophenol hydroxylase"
;[893..900]:substance:"acetone"
(SENT
  (S
    (NP-SBJ (DT:[763..767] Each) (NN:[768..776] compound))
    (VP (VBD:[778..787] displayed)
      (NP
        (NP (JJ:[788..799] competitive) (NN:[800..810] inhibition))
        (PP (IN:[811..813] of)
          (NP
             (NN:[814..827] p-nitrophenol) (NN:[828..839] hydroxylase)
            (NN:[840..848] activity))))
      (PP (IN:[849..851] in)
        (NP
          (NP (NNS:[853..864] incubations))
          (VP (VBG:[865..870] using)
            (NP
              (NP (NN:[871..876] liver) (NNS:[877..887] microsomes))
              (PP (IN:[888..892] from)
                (NP
                  (ADJP (NN:[893..900] acetone) (HYPH:[900..901] -)
                        (VBN:[901..911] pretreated))
                  (JJ:[912..916] male)
                  (NML (NNP:[917..924] Sprague) (HYPH:[924..925] -)
                       (NNP:[925..931] Dawley))
                  (NNS:[933..937] rats))))))))
    (.:[937..938] .)))

;sentence 8 Span:939..1284
;Preincubation of the microsomes with DASO2 inactivated p-nitrophenol 
;hydroxylase activity in a process that was time- and NADPH-dependent and 
;saturable, exhibited pseudo-first-order kinetics, was protected by alternate 
;substrate, was accompanied by a loss of microsomal P-450-CO binding spectrum,
; and was unaffected by exogenous nucleophile.
;[976..981]:substance:"DASO2"
;[994..1020]:cyp450:"p-nitrophenol  hydroxylase"
;[1062..1067]:substance:"NADPH"
;[1161..1170]:substance:"substrate"
;[1212..1217]:cyp450:"P-450"
;[1218..1220]:substance:"CO"
;[1272..1283]:substance:"nucleophile"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[939..952] Preincubation))
      (PP (IN:[953..955] of)
        (NP (DT:[956..959] the) (NNS:[960..970] microsomes)))
      (PP (IN:[971..975] with)
        (NP (NN:[976..981] DASO2))))
    (VP (VBD:[982..993] inactivated)
      (NP
         (NN:[994..1007] p-nitrophenol) (NN:[1009..1020] hydroxylase)
        (NN:[1021..1029] activity))
      (PP (IN:[1030..1032] in)
        (NP
          (NP (DT:[1033..1034] a) (NN:[1035..1042] process))
          (SBAR
            (WHNP-2 (WDT:[1043..1047] that))
            (S
              (NP-SBJ-2 (-NONE-:[1047..1047] *T*))
              (VP
                (VP (VBD:[1048..1051] was)
                  (ADJP-PRD
                    (ADJP
                      (ADJP (NN:[1052..1056] time) (HYPH:[1056..1057] -)
                        (ADJP-1 (-NONE-:[1057..1057] *P*)))
                      (CC:[1058..1061] and)
                      (ADJP (NN:[1062..1067] NADPH) (HYPH:[1067..1068] -)
                        (ADJP-1 (JJ:[1068..1077] dependent))))
                    (CC:[1078..1081] and)
                    (ADJP (JJ:[1083..1092] saturable))))
                (,:[1092..1093] ,)
                (VP (VBD:[1094..1103] exhibited)
                  (NP
                    (NML (AFX:[1104..1110] pseudo) (HYPH:[1110..1111] -)
                         (JJ:[1111..1116] first) (HYPH:[1116..1117] -)
                         (NN:[1117..1122] order))
                    (NNS:[1123..1131] kinetics)))
                (,:[1131..1132] ,)
                (VP (VBD:[1133..1136] was)
                  (VP (VBN:[1137..1146] protected)
                    (NP-2 (-NONE-:[1146..1146] *))
                    (PP (IN:[1147..1149] by)
                      (NP-LGS (JJ:[1150..1159] alternate)
                              (NN:[1161..1170] substrate)))))
                (,:[1170..1171] ,)
                (VP (VBD:[1172..1175] was)
                  (VP (VBN:[1176..1187] accompanied)
                    (NP-2 (-NONE-:[1187..1187] *))
                    (PP (IN:[1188..1190] by)
                      (NP-LGS
                        (NP (DT:[1191..1192] a) (NN:[1193..1197] loss))
                        (PP (IN:[1198..1200] of)
                          (NP (JJ:[1201..1211] microsomal)
                            (NML (NN:[1212..1217] P-450) (HYPH:[1217..1218] -)
                                 (NN:[1218..1220] CO))
                            (NN:[1221..1228] binding) (NN:[1229..1237] spectrum)))))))
                (,:[1237..1238] ,) (CC:[1240..1243] and)
                (VP (VBD:[1244..1247] was)
                  (ADJP-PRD (JJ:[1248..1258] unaffected))
                  (PP (IN:[1259..1261] by)
                    (NP (JJ:[1262..1271] exogenous)
                        (NN:[1272..1283] nucleophile))))))))))
    (.:[1283..1284] .)))

;sentence 9 Span:1285..1376
;The Ki value for DASO2 was 188  microM and the maximal rate of inactivation
;was 0.32 min-1.
;[1289..1291]:quantitative-name:"Ki"
;[1302..1307]:substance:"DASO2"
;[1312..1315]:quantitative-value:"188"
;[1317..1323]:quantitative-units:"microM"
;[1365..1369]:quantitative-value:"0.32"
;[1370..1375]:quantitative-units:"min-1"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[1285..1288] The) (NN:[1289..1291] Ki) (NN:[1292..1297] value))
        (PP (IN:[1298..1301] for)
          (NP (NN:[1302..1307] DASO2))))
      (VP (VBD:[1308..1311] was)
        (NP-PRD (CD:[1312..1315] 188) (NN:[1317..1323] microM))))
    (CC:[1324..1327] and)
    (S
      (NP-SBJ
        (NP (DT:[1328..1331] the) (JJ:[1332..1339] maximal)
            (NN:[1340..1344] rate))
        (PP (IN:[1345..1347] of)
          (NP (NN:[1348..1360] inactivation))))
      (VP (VBD:[1361..1364] was)
        (NP-PRD (CD:[1365..1369] 0.32) (NN:[1370..1375] min-1))))
    (.:[1375..1376] .)))

;sentence 10 Span:1377..1519
;DASO2 was  ineffective in the inactivation of ethoxyresorufin dealkylase,
;pentoxyresorufin  dealkylase, or benzphetamine demethylase activity.
;[1377..1382]:substance:"DASO2"
;[1423..1449]:cyp450:"ethoxyresorufin dealkylase"
;[1451..1479]:cyp450:"pentoxyresorufin  dealkylase"
;[1484..1509]:cyp450:"benzphetamine demethylase"
(SENT
  (S
    (NP-SBJ (NN:[1377..1382] DASO2))
    (VP (VBD:[1383..1386] was)
      (ADJP-PRD (JJ:[1388..1399] ineffective))
      (PP (IN:[1400..1402] in)
        (NP
          (NP (DT:[1403..1406] the) (NN:[1407..1419] inactivation))
          (PP (IN:[1420..1422] of)
            (NP
              (NP
                (NML (NN:[1423..1438] ethoxyresorufin)
                     (NN:[1439..1449] dealkylase))
                (NML-1 (-NONE-:[1449..1449] *P*)))
              (,:[1449..1450] ,)
              (NP
                (NML (NN:[1451..1467] pentoxyresorufin)
                     (NN:[1469..1479] dealkylase))
                (NML-1 (-NONE-:[1479..1479] *P*)))
              (,:[1479..1480] ,) (CC:[1481..1483] or)
              (NP
                (NML (NN:[1484..1497] benzphetamine)
                     (NN:[1498..1509] demethylase))
                (NML-1 (NN:[1510..1518] activity))))))))
    (.:[1518..1519] .)))

;sentence 11 Span:1520..1630
;Purified P-450 2E1 in a  reconstituted system was inactivated in a time- and
;NADPH-dependent manner by  DASO2.
;[1529..1538]:cyp450:"P-450 2E1"
;[1597..1602]:substance:"NADPH"
;[1624..1629]:substance:"DASO2"
(SENT
  (S
    (NP-SBJ-2
      (NP (VBN:[1520..1528] Purified)
         (NN:[1529..1534] P-450) (NN:[1535..1538] 2E1))
      (PP (IN:[1539..1541] in)
        (NP (DT:[1542..1543] a) (VBN:[1545..1558] reconstituted)
            (NN:[1559..1565] system))))
    (VP (VBD:[1566..1569] was)
      (VP (VBN:[1570..1581] inactivated)
        (NP-2 (-NONE-:[1581..1581] *))
        (PP (IN:[1582..1584] in)
          (NP (DT:[1585..1586] a)
            (ADJP
              (ADJP (NN:[1587..1591] time) (HYPH:[1591..1592] -)
                (ADJP-1 (-NONE-:[1592..1592] *P*)))
              (CC:[1593..1596] and)
              (ADJP (NN:[1597..1602] NADPH) (HYPH:[1602..1603] -)
                (ADJP-1 (JJ:[1603..1612] dependent))))
            (NN:[1613..1619] manner)))
        (PP (IN:[1620..1622] by)
          (NP-LGS (NN:[1624..1629] DASO2)))))
    (.:[1629..1630] .)))

;sentence 12 Span:1631..1739
;The metabolic conversion of diallyl sulfide to the sulfoxide and sulfone  was
;observed in vivo and in vitro.
;[1659..1674]:substance:"diallyl sulfide"
;[1682..1691]:substance:"sulfoxide"
;[1696..1703]:substance:"sulfone"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1631..1634] The) (JJ:[1635..1644] metabolic)
          (NN:[1645..1655] conversion))
      (PP (IN:[1656..1658] of)
        (NP (JJ:[1659..1666] diallyl) (NN:[1667..1674] sulfide)))
      (PP (TO:[1675..1677] to)
        (NP (DT:[1678..1681] the) (NN:[1682..1691] sulfoxide)
            (CC:[1692..1695] and) (NN:[1696..1703] sulfone))))
    (VP (VBD:[1705..1708] was)
      (VP (VBN:[1709..1717] observed)
        (NP-1 (-NONE-:[1717..1717] *))
        (ADVP
          (ADVP (FW:[1718..1720] in) (FW:[1721..1725] vivo))
          (CC:[1726..1729] and)
          (ADVP (FW:[1730..1732] in) (FW:[1733..1738] vitro)))))
    (.:[1738..1739] .)))

;sentence 13 Span:1740..1940
;The results suggest that diallyl sulfide  inhibits the metabolism of P-450
;2E1 substrates by competitive inhibition  mechanisms and by inactivating
;P-450 2E1 via a suicide-inhibitory action of  DASO2.
;[1765..1780]:substance:"diallyl sulfide"
;[1809..1818]:cyp450:"P-450 2E1"
;[1819..1829]:substance:"substrates"
;[1888..1897]:cyp450:"P-450 2E1"
;[1934..1939]:substance:"DASO2"
(SENT
  (S
    (NP-SBJ (DT:[1740..1743] The) (NNS:[1744..1751] results))
    (VP (VBP:[1752..1759] suggest)
      (SBAR (IN:[1760..1764] that)
        (S
          (NP-SBJ (JJ:[1765..1772] diallyl) (NN:[1773..1780] sulfide))
          (VP (VBZ:[1782..1790] inhibits)
            (NP
              (NP (DT:[1791..1794] the) (NN:[1795..1805] metabolism))
              (PP (IN:[1806..1808] of)
                (NP
                  (NML (NN:[1809..1814] P-450) (NN:[1815..1818] 2E1))
                  (NNS:[1819..1829] substrates))))
            (PP-MNR
              (PP (IN:[1830..1832] by)
                (NP (JJ:[1833..1844] competitive) (NN:[1845..1855] inhibition)
                    (NNS:[1857..1867] mechanisms)))
              (CC:[1868..1871] and)
              (PP (IN:[1872..1874] by)
                (S-NOM
                  (NP-SBJ (-NONE-:[1874..1874] *))
                  (VP (VBG:[1875..1887] inactivating)
                    (NP (NN:[1888..1893] P-450) (NN:[1894..1897] 2E1))
                    (PP-MNR (IN:[1898..1901] via)
                      (NP
                        (NP (DT:[1902..1903] a)
                          (ADJP (NN:[1904..1911] suicide) (HYPH:[1911..1912] -)
                                (JJ:[1912..1922] inhibitory))
                          (NN:[1923..1929] action))
                        (PP (IN:[1930..1932] of)
                          (NP (NN:[1934..1939] DASO2)))))))))))))
    (.:[1939..1940] .)))

;section 14 Span:1944..1988
;PMID: 1807447 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1944..1948] PMID) (::[1948..1949] :) (CD:[1950..1957] 1807447)
        (NN:[1958..1959] -LSB-) (NNP:[1959..1965] PubMed) (::[1966..1967] -)
        (NN:[1968..1975] indexed) (IN:[1976..1979] for)
        (NNP:[1980..1988] MEDLINE-RSB-)))
